RxDoctor Payments Data

Sindhu Mittadoddi, MD

Geriatric Medicine · Bronx, NYNPI 1306299573

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 30.2% of the total. 2025 is the largest year on record at $1,298, more than ten times the $109 reported in 2020.

$2,165in general payments, 2019–2025

Across 76 payments — averaging $28.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$653
  • EMD Serono, Inc.$447
  • Viiv Healthcare Company$297
  • AstraZeneca$297
  • Neurocrine Biosciences, Inc.$245
  • Gilead$173
  • plus $53 from 2 others

What the payments were for

  • Food & beverage$2,165100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,165 in reported general payments places this provider in the 85th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$209,776
Medicare patients
258
Services billed
2,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$27,623
EntrestoSacubitril/Valsartan22$10,549
AbrysvoRsv Vacc, Pref A And Pref B/Pf31$9,764
JanuviaSitagliptin Phosphate23$7,172
FarxigaDapagliflozin Propanediol16$4,572
Incruse ElliptaUmeclidinium Bromide12$4,418
Atorvastatin Calcium183$3,180
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,299
Mirtazapine68$1,747
Memantine Hcl28$1,704
Quetiapine Fumarate70$1,500
Memantine Hcl ErMemantine Hcl12$1,498
Olanzapine39$1,452
Aripiprazole21$1,450
Amlodipine Besylate108$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$297$4,57216 claims
Lilly USA, LLCOlanzapine$22$1,45239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →